CN117054649A - Chronic atrophic gastritis transformation marker for stomach cancer and application thereof - Google Patents
Chronic atrophic gastritis transformation marker for stomach cancer and application thereof Download PDFInfo
- Publication number
- CN117054649A CN117054649A CN202310977830.9A CN202310977830A CN117054649A CN 117054649 A CN117054649 A CN 117054649A CN 202310977830 A CN202310977830 A CN 202310977830A CN 117054649 A CN117054649 A CN 117054649A
- Authority
- CN
- China
- Prior art keywords
- pmn
- atrophic gastritis
- chronic atrophic
- human
- mdscs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 42
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 40
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 40
- 208000016644 chronic atrophic gastritis Diseases 0.000 title claims abstract description 36
- 239000003550 marker Substances 0.000 title claims abstract description 15
- 230000009466 transformation Effects 0.000 title description 2
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims abstract description 36
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 238000000684 flow cytometry Methods 0.000 claims description 9
- 210000005259 peripheral blood Anatomy 0.000 claims description 8
- 239000011886 peripheral blood Substances 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 6
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 5
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 5
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 5
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 5
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 5
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 5
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 5
- 230000001131 transforming effect Effects 0.000 claims description 4
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 3
- 239000000523 sample Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 102000046699 human CD14 Human genes 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 abstract description 11
- 206010028980 Neoplasm Diseases 0.000 abstract description 11
- 201000011510 cancer Diseases 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 230000011218 segmentation Effects 0.000 abstract description 4
- 230000002596 correlated effect Effects 0.000 abstract description 3
- 238000013399 early diagnosis Methods 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000004364 calculation method Methods 0.000 abstract description 2
- 238000013517 stratification Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 4
- 238000012502 risk assessment Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010067994 Mucosal atrophy Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a marker for converting chronic atrophic gastritis into gastric cancer and application thereof, wherein the marker is PMN-MDSCs. The invention discovers that the expression level of PMN-MDSCs is gradually up-regulated along with the progress of gastric inflammation-cancer for the first time, and the PMN-MDSCs content is positively correlated with the OLGA classification stage of patients with chronic atrophic gastritis. Further calculation of the segmentation efficacy of PMN-MDSCs for OLGAIII/IV segmentation revealed an area under the ROC curve of 0.9333, a sensitivity of 1 and a specificity of 0.8. Therefore, the PMN-MDSCs can be used as a specific marker for converting chronic atrophic gastritis into gastric cancer, has excellent diagnosis efficacy on patients with high canceration risk of chronic atrophic gastritis, is beneficial to carrying out dangerous stratification on the patients with chronic atrophic gastritis, and screens out patients with high risk of gastric cancer, thereby realizing early diagnosis and early treatment of gastric cancer.
Description
Technical Field
The invention belongs to the technical field of molecular diagnosis, and particularly relates to a marker for converting chronic atrophic gastritis into gastric cancer and application thereof.
Background
About 41 ten thousand new stomach cancers in China every year belong to major chronic non-infectious diseases affecting national health, and reducing the incidence rate and the death rate of stomach cancers in China becomes a major public health problem to be solved urgently. Stomach cancer in China is mainly intestinal type stomach cancer, and the intestinal type stomach cancer has a relatively fixed evolution form, namely, the stomach cancer starts from chronic inflammation and develops into chronic atrophic gastritis (chronic atrophic gastritis, CAG), intestinal metaplasia and intraepithelial neoplasia, and finally reaches stomach cancer. Among them, chronic atrophic gastritis and its associated intestinal metaplasia and intraepithelial neoplasia are important precancerous diseases, and are closely related to the occurrence of gastric cancer. Therefore, the development of biomarkers capable of monitoring the conversion of chronic atrophic gastritis "inflammatory-cancer" and predicting the risk of gastric cancer is of great importance for the early diagnosis and treatment of gastric cancer.
Myeloid-lineage suppressor cells (MDSCs) are a population of cells with potent immunosuppressive effects that play a key role in creating an immunosuppressive microenvironment. MDSCs are largely expanded from the normal differentiation of myeloid cells. Under normal physiological conditions, hematopoietic stem cells differentiate into common myeloid progenitor cells, which are subdivided into Immature Myeloid Cells (IMCs), which further differentiate into mature neutrophils, macrophages or dendritic cells. When the organism is subjected to pathological conditions such as tumor, inflammation, infection, wound and the like, the normal differentiation of the IMCs can be blocked by inflammatory factors or cytokines from tumor sources, the IMCs are induced to become MDSCs, and the MDSCs are recruited, amplified and activated in peripheral blood, bone marrow or pathological parts. Whether MDSCs can recognize gastric cancer risk in patients with chronic atrophic gastritis has not been reported.
Disclosure of Invention
Based on the above, the invention aims to provide a PMN-MDSC (permanent magnet synchronous motor) as a marker for converting chronic atrophic gastritis into gastric cancer and application thereof in preparing a reagent for evaluating the risk of converting chronic atrophic gastritis into gastric cancer.
In order to achieve the above purpose, the present invention adopts the following technical scheme.
The application of human PMN-MDSC as a marker in preparing a reagent for evaluating the risk of transforming chronic atrophic gastritis into gastric cancer.
The invention also provides application of the reagent for detecting the content of the human PMN-MDSC in the biological sample in preparing a product for evaluating the risk of converting chronic atrophic gastritis into gastric cancer.
In some embodiments, the biological sample is a human peripheral blood sample.
In some embodiments, the product is a human flow cytometry detection kit.
The invention also provides application of the human PMN-MDSC as a marker in screening a reagent for evaluating the risk of transforming chronic atrophic gastritis into gastric cancer.
In some embodiments, the flow cytometry analysis of the human PMN-MDSC is labeled as
HLA-DR - CD11b + CD14 - CD15 + HLA-DR negative, CD11b positive, CD14 negative, CD15 positive.
The invention also provides a risk assessment kit for converting chronic atrophic gastritis into gastric cancer, which comprises a reagent for detecting the content of human PMN-MDSC in a biological sample.
In some embodiments, the reagent comprises the following antibodies: human HLA-DR antibodies, human CD11b antibodies, human CD14 antibodies, human CD15 antibodies.
In some embodiments, the antibodies are modified with different fluorescent groups.
In some embodiments, the kit is a human flow cytometry detection kit.
According to the invention, the first time of research discovers that the expression level of PMN-MDSCs in blood samples of patients with chronic superficial gastritis, chronic atrophic gastritis and gastric cancer is gradually up-regulated along with the progress of gastric inflammation-cancer, and the difference has statistical significance. PMN-MDSCs levels correlated positively with OLGA grading in patients with chronic atrophic gastritis (r=0.6427, p=0.0072). Further calculation of the segmentation efficacy of PMN-MDSCs for OLGAIII/IV segmentation, found an area under ROC curve of 0.9333, sensitivity of 1, specificity of 0.8, p=0.0048. Therefore, the PMN-MDSCs can be used as a specific marker for converting chronic atrophic gastritis into gastric cancer, has excellent diagnosis efficacy on patients with high canceration risk of chronic atrophic gastritis, is beneficial to carrying out dangerous stratification on the patients with chronic atrophic gastritis, and screens out patients with high risk of gastric cancer, thereby realizing early diagnosis and early treatment of gastric cancer.
Drawings
FIG. 1 shows typical flow cytometry detection analysis results.
FIG. 2 is a graph showing the results of statistical analysis of PMN-MDSCs content in biological samples from various groups of patients.
FIG. 3 is a correlation analysis of PMN-MDSCs with OLGA fractionation stage.
FIG. 4 shows the results of ROC curve analysis of PMN-MDSCs for assessing gastric cancer risk.
Detailed Description
The experimental methods of the present invention, in which specific conditions are not specified in the following examples, are generally conducted under conventional conditions or under conditions recommended by the manufacturer. The various chemicals commonly used in the examples are commercially available.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The terms "comprising" and "having" and any variations thereof, are intended to cover a non-exclusive inclusion. For example, a process, method, apparatus, article, or device that comprises a list of steps is not limited to the elements or modules listed but may alternatively include additional steps not listed or inherent to such process, method, article, or device.
In the present invention, the term "plurality" means two or more. "and/or", describes an association relationship of an association object, and indicates that there may be three relationships, for example, a and/or B, and may indicate: a exists alone, A and B exist together, and B exists alone. The character "/" generally indicates that the context-dependent object is an "or" relationship.
The international atrophy study group in 2005 proposed a grading and staging standard for gastric mucosal inflammatory response, degree and extent of atrophy (i.e., chronic gastritis OLGA grading and staging system). The system evaluates the risk of cancerous changes based on the extent and degree of gastric mucosal atrophy.
OLGA staging is as follows:
wherein, the stage (III/IV) of the high-risk OLGA is closely related to the high risk of gastric cancer, and the stage III and IV belong to patients with high risk of gastric cancer.
The following description is made with reference to specific embodiments.
Example 1
The content of PMN-MDSCs in peripheral blood samples of 15 cases of chronic superficial gastritis (CNAG), 16 cases of Chronic Atrophic Gastritis (CAG) and 7 cases of Gastric Cancer (GC) was examined by flow cytometry. All patients who were included in the test were clinically diagnosed patients, and peripheral blood of the patients was collected by anticoagulation of venous EDTA after informed consent was signed with the patients.
Mononuclear lymphocytes (PBMCs) were isolated from all peripheral blood samples using lymphocyte separation fluids (Tianjin, ocean), and the procedure was strictly followed according to the kit instructions. PBMC obtained by separation are stained as follows:
(1) Each sample is 1 x 10 6 Adding PBMC into a flow tube, adding 5ml PBS buffer solution, mixing well, centrifuging at 2000rpm/min for 5min, discarding the supernatant, and collecting cell precipitate;
(2) Adding 100 μl of a flow antibody dilution comprising human HLA-DR-APC-cy 7 antibody, human CD11 b-BUV 396 antibody, human CD 14-APC antibody, human CD 15-BV 605 body to the cell pellet according to 1:200, adding all kinds of antibodies into PBS buffer solution for dilution to obtain the streaming antibody dilution;
(3) Placing the flow tube on a vortex oscillator for uniform vibration and mixing, and then dyeing for 30min at 4 ℃ in a dark place;
(4) Adding precooled PBS buffer solution into a flow tube, centrifuging at 2000rpm/min for 5min, and discarding the supernatant; cells were resuspended in 300 μl of pre-chilled PBS buffer, then detected on-press using a flow analyzer (BD Canto II, USA), data obtained, and analyzed using FlowJo10 software.
Statistical analysis: the correlation analysis discusses the phase correlation of PMN-MDSCs and OLGA by adopting the rank sum test in IBM SPSS statistical software to carry out the group comparison, and the ROC curve detects the diagnosis efficacy of PMN-MDSCs on patients with high risk of gastric cancer. The difference was considered statistically significant with P < 0.05.
FIG. 1 shows typical flow cytometry detection analysis results. As shown in FIG. 2, the PMN-MDSCs content in peripheral blood of GC patients is significantly higher than that of CAG patients and CNAG patients; and the PMN-MDSCs content in the peripheral blood of the CAG patient is obviously higher than that of the CNAG patient. The expression level of PMN-MDSCs in blood samples of patients with chronic superficial gastritis, chronic atrophic gastritis and gastric cancer is gradually up-regulated along with the progress of gastric inflammation-cancer, and the PMN-MDSCs are suggested to be used as gastric inflammation-cancer risk assessment markers.
Further, to evaluate the efficacy of PMN-MDSCs as a marker for gastric "inflammation-cancer" risk assessment, CAG patients were classified into low risk patients (stage i and stage ii) groups (10 cases) and high risk patients (stage iii and stage iv) groups (6 cases) according to OLGA classification, and the correlation between PMN-MDSCs and OLGA classification was analyzed. As shown in fig. 3, PMN-MDSCs correlated positively with OLGA fractionation stage (r=0.6427, p=0.0072). The ROC curve analysis result shows that when PMN-MDSCs are used for evaluating the risk of gastric cancer (high risk in III phase and IV phase), the area under the curve is 0.9333, the sensitivity is 1, the specificity is 0.8, p=0.0048, and the diagnosis performance is good, so that the PMN-MDSCs can be used as a specific marker for evaluating the risk of gastric "inflammation-cancer".
In conclusion, the invention discovers that the expression level of PMN-MDSCs in blood samples of patients with chronic superficial gastritis, chronic atrophic gastritis and gastric cancer is gradually up-regulated along with the progress of gastric inflammation-cancer, is positively related to the stage of OLGA grading, can be used as a specific marker for risk assessment of gastric inflammation-cancer, and has better diagnosis performance.
The technical features of the above embodiments may be arbitrarily combined, and all possible combinations of the technical features in the above embodiments are not described for brevity of description, however, as long as there is no contradiction between the combinations of the technical features, they should be considered as the scope of the description.
The foregoing examples illustrate only a few embodiments of the invention and are described in detail herein without thereby limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention. Accordingly, the scope of protection of the present invention is to be determined by the appended claims.
Claims (10)
1. The application of human PMN-MDSC as a marker in preparing a reagent for evaluating the risk of transforming chronic atrophic gastritis into gastric cancer.
2. The application of a reagent for detecting the content of human PMN-MDSC in biological samples in preparing a product for evaluating the risk of converting chronic atrophic gastritis into gastric cancer.
3. The use according to claim 2, wherein the biological sample is a human peripheral blood sample.
4. The use according to claim 2, wherein the product is a human flow cytometry detection kit.
5. The application of human PMN-MDSC as a marker in screening a reagent for evaluating the risk of transforming chronic atrophic gastritis into gastric cancer.
6. The use according to any one of claims 1 to 4, wherein the flow cytometry analysis markers of human PMN-MDSC are HLA-DR - CD11b + CD14 - CD15 + 。
7. A kit for assessing the risk of conversion of chronic atrophic gastritis to gastric cancer, wherein the kit comprises reagents for detecting the level of human PMN-MDSC in a biological sample.
8. The kit of claim 6, wherein the reagents comprise the following antibodies: human HLA-DR antibodies, human CD11b antibodies, human CD14 antibodies, human CD15 antibodies.
9. The kit of claim 7, wherein the antibodies are modified with different fluorophores.
10. The kit of any one of claims 7 to 9, wherein the kit is a human flow cytometry detection kit.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310977830.9A CN117054649A (en) | 2023-08-04 | 2023-08-04 | Chronic atrophic gastritis transformation marker for stomach cancer and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310977830.9A CN117054649A (en) | 2023-08-04 | 2023-08-04 | Chronic atrophic gastritis transformation marker for stomach cancer and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117054649A true CN117054649A (en) | 2023-11-14 |
Family
ID=88665603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310977830.9A Pending CN117054649A (en) | 2023-08-04 | 2023-08-04 | Chronic atrophic gastritis transformation marker for stomach cancer and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117054649A (en) |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102037015A (en) * | 2007-09-21 | 2011-04-27 | 健泰科生物技术公司 | Inhibition of angiogenesis |
| US20120070461A1 (en) * | 2010-09-21 | 2012-03-22 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| CN104024276A (en) * | 2012-06-21 | 2014-09-03 | 卡姆普根有限公司 | LSR antibodies, and uses thereof for treatment of cancer |
| US20150150940A1 (en) * | 2012-05-21 | 2015-06-04 | The Trustees Of Columbia University In The City Of New York | Trefoil family factor proteins and uses thereof |
| US20170247464A1 (en) * | 2014-10-24 | 2017-08-31 | Ose Immunotherapeutics | Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases |
| CN107271675A (en) * | 2017-03-24 | 2017-10-20 | 郑猛 | Anti-human ADRB3 monoclonal antibodies and its application in medical diagnosis on disease and treatment |
| CN107533065A (en) * | 2015-03-13 | 2018-01-02 | 布莱恩·J·赫尔尼奇 | CD4 is monitored in cancer and immune restoration+The method of 1 type t helper cell response |
| US20180164313A1 (en) * | 2015-06-01 | 2018-06-14 | The Wistar Institute Of Anatomy And Biology | Methods for monitoring polymorphonuclear myeloid derived suppressor cells |
| US20180252721A1 (en) * | 2015-09-02 | 2018-09-06 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
| CN108982857A (en) * | 2018-09-16 | 2018-12-11 | 上海中医药大学附属龙华医院 | The detection method and its application of a kind of Non-small cell lung carcinoma peripheral blood marrow source property inhibition cell |
| CN109517897A (en) * | 2011-04-28 | 2019-03-26 | 南加利福尼亚大学 | Mankind's marrow source inhibitory cells cancer markers |
| US20210077582A1 (en) * | 2019-09-13 | 2021-03-18 | Duke University | Compositions and methods for increasing the efficacy of anti-pd-1 antibody immunotherapy |
| CN114814209A (en) * | 2022-04-29 | 2022-07-29 | 中山大学附属第一医院 | Early warning detection marker PMN-MDSC for early diagnosis of premature BPD |
| WO2023012844A1 (en) * | 2021-08-02 | 2023-02-09 | Ospedale Pediatrico Bambino Gesu' | Antigen cd111 as a new specific diagnostic and therapeutic marker for polymorphonuclear myeloid-derived suppressor cells (pmn-mdscs) |
| CN116240277A (en) * | 2022-07-11 | 2023-06-09 | 复旦大学附属儿科医院 | Malat 1-mediated polymorphonuclear myeloid-derived suppressor cell production and its use in sepsis |
| CN116380755A (en) * | 2023-03-20 | 2023-07-04 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | CD127 + Application of PMN-MDSCs in diagnosis of bronchopulmonary dysplasia and diagnostic kit |
-
2023
- 2023-08-04 CN CN202310977830.9A patent/CN117054649A/en active Pending
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102037015A (en) * | 2007-09-21 | 2011-04-27 | 健泰科生物技术公司 | Inhibition of angiogenesis |
| US20120070461A1 (en) * | 2010-09-21 | 2012-03-22 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| CN103180739A (en) * | 2010-09-21 | 2013-06-26 | 伊玛提克斯生物技术有限公司 | Use of myeloid cell biomarkers for the diagnosis of cancer |
| CN109517897A (en) * | 2011-04-28 | 2019-03-26 | 南加利福尼亚大学 | Mankind's marrow source inhibitory cells cancer markers |
| US20150150940A1 (en) * | 2012-05-21 | 2015-06-04 | The Trustees Of Columbia University In The City Of New York | Trefoil family factor proteins and uses thereof |
| CN104024276A (en) * | 2012-06-21 | 2014-09-03 | 卡姆普根有限公司 | LSR antibodies, and uses thereof for treatment of cancer |
| US20170247464A1 (en) * | 2014-10-24 | 2017-08-31 | Ose Immunotherapeutics | Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases |
| CN107533065A (en) * | 2015-03-13 | 2018-01-02 | 布莱恩·J·赫尔尼奇 | CD4 is monitored in cancer and immune restoration+The method of 1 type t helper cell response |
| US20180164313A1 (en) * | 2015-06-01 | 2018-06-14 | The Wistar Institute Of Anatomy And Biology | Methods for monitoring polymorphonuclear myeloid derived suppressor cells |
| US20180252721A1 (en) * | 2015-09-02 | 2018-09-06 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
| CN107271675A (en) * | 2017-03-24 | 2017-10-20 | 郑猛 | Anti-human ADRB3 monoclonal antibodies and its application in medical diagnosis on disease and treatment |
| CN108982857A (en) * | 2018-09-16 | 2018-12-11 | 上海中医药大学附属龙华医院 | The detection method and its application of a kind of Non-small cell lung carcinoma peripheral blood marrow source property inhibition cell |
| US20210077582A1 (en) * | 2019-09-13 | 2021-03-18 | Duke University | Compositions and methods for increasing the efficacy of anti-pd-1 antibody immunotherapy |
| WO2023012844A1 (en) * | 2021-08-02 | 2023-02-09 | Ospedale Pediatrico Bambino Gesu' | Antigen cd111 as a new specific diagnostic and therapeutic marker for polymorphonuclear myeloid-derived suppressor cells (pmn-mdscs) |
| CN114814209A (en) * | 2022-04-29 | 2022-07-29 | 中山大学附属第一医院 | Early warning detection marker PMN-MDSC for early diagnosis of premature BPD |
| CN116240277A (en) * | 2022-07-11 | 2023-06-09 | 复旦大学附属儿科医院 | Malat 1-mediated polymorphonuclear myeloid-derived suppressor cell production and its use in sepsis |
| CN116380755A (en) * | 2023-03-20 | 2023-07-04 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | CD127 + Application of PMN-MDSCs in diagnosis of bronchopulmonary dysplasia and diagnostic kit |
Non-Patent Citations (15)
| Title |
|---|
| ECE TAVUKCUOGLU等: "Human splenic polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are strategically located immune regulatory cells in cancer", EUR J IMMUNOL, vol. 50, no. 12, 31 December 2020 (2020-12-31), pages 2067 - 2074 * |
| LINDA WANG等: "Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins", J IMMUNOL, vol. 190, no. 2, 15 January 2023 (2023-01-15), pages 794 - 804, XP055570349, DOI: 10.4049/jimmunol.1202088 * |
| ZHOU XINGYU等: "PMN-MDSCs accumulation induced by CXCL1 promotes CD8+ T cells exhaustion in gastric cancer", CANCER LETTERS, vol. 532, 28 April 2022 (2022-04-28), pages 215598 * |
| 刘鹏等: "肿瘤免疫细胞因子与慢性萎缩性胃炎"炎-癌转化"研究进展", 中华中医药杂志, vol. 37, no. 6, 9 August 2022 (2022-08-09), pages 3346 - 3351 * |
| 叶妮: "免疫抑制性细胞Treg/Th17、MDSCs在胃癌发生发展中作用的临床研究", 万方学位论文, 16 September 2013 (2013-09-16) * |
| 周佳杰: "髓源性抑制细胞在胃癌患者外周血和肿瘤灶中的表达水平及临床意义", 万方学位论文, 31 October 2012 (2012-10-31) * |
| 屠妍霞等: "髓源性抑制细胞在胃癌发生发展中的作用与应用", 哈尔滨医药, vol. 40, no. 05, 25 October 2020 (2020-10-25), pages 490 - 493 * |
| 朱立宁: "幽门螺杆菌感染诱导髓源抑制细胞致胃癌肿瘤免疫逃逸的临床研究", 万方学位论文, 3 September 2012 (2012-09-03), pages 4 - 1 * |
| 朱立宁等: "髓源抑制细胞与慢性胃炎至胃癌演变的相关性", 中华消化杂志, vol. 32, no. 9, 5 December 2012 (2012-12-05) * |
| 李晓宁: "胃癌患者外周血MDSC特点及其与中医证型关系的研究", 万方学位论文, 27 March 2019 (2019-03-27) * |
| 杨梅: "髓源性抑制细胞在胃癌发展机制中的研究", 中国优秀硕士学位论文全文数据库 医药卫生科技辑, no. 1, 15 January 2020 (2020-01-15), pages 1 - 2 * |
| 王文娟: "LTBP4在胃腺癌中的表达与相应的机制研究", 中国优秀硕士学位论文全文数据库 医药卫生科技辑, no. 05, 15 May 2023 (2023-05-15) * |
| 郑志华: "基于MDSCs探讨慢性萎缩性胃炎表型特征及健脾清热活血方的干预研究", 中国优秀硕士学位论文全文数据库 医药卫生科技辑, no. 01, 15 January 2023 (2023-01-15) * |
| 郭维华等: "《口腔细胞实验操作技术》", 30 June 2021, 四川大学出版社, pages: 145 * |
| 鲁翔等: "《癌症的免疫治疗》", 31 October 2019, 东南大学出版社, pages: 467 - 468 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6485759B2 (en) | Method for detecting malignancy of peripheral circulating tumor cell unit and kit thereof | |
| CN116699131B (en) | HLA-DR+CD14+CD56+Use of monocytes for diagnosis in HLH | |
| US20210106997A1 (en) | Column-based device and method for retrieval of rare cells based on size, and uses thereof | |
| Davies et al. | Patients with primary Sjögren's syndrome have alterations in absolute quantities of specific peripheral leucocyte populations | |
| CN113484520A (en) | Molecular marker and application thereof in detection of angioimmunoblastic T-cell lymphoma | |
| CN115327118A (en) | CD38 + HLA-DR + CD8 + Application of T cells in early diagnosis of GVHD | |
| Schreier et al. | An update of circulating rare cell types in healthy adult peripheral blood: findings of immature erythroid precursors | |
| CN114894698B (en) | Application of MDSCs in diagnosis and/or typing of aplastic anemia | |
| CN117054649A (en) | Chronic atrophic gastritis transformation marker for stomach cancer and application thereof | |
| CN109975548B (en) | Application of IgG4 detection reagent in preparation of colorectal cancer diagnostic agent | |
| CN116298275A (en) | NK cell subset of hematophagous lymphocytosis diagnostic marker and application thereof | |
| Pliyev et al. | Circulating CD35−/CD49d+ neutrophils in influenza virus infection patients | |
| Siemińska et al. | The level of myeloid derived-suppressor cells in peripheral blood of patients with prostate cancerafter various types of therapy | |
| CN116064225A (en) | Microfluidic chip for detecting circulating tumor cells and preparation method and application thereof | |
| Pertiwi et al. | Hematological and Biochemical Parameters at Admission as Predictors for Mortality in Patients with Moderate to Severe COVID-19 | |
| WO2003098212B1 (en) | Method of isolating an endotehelial cell and method of donor specific crossmatching | |
| Hoedemakers et al. | Performance characteristics of blast flagging on the Cell Dyn 4000 haematology analyser | |
| CN116990514A (en) | Lymphoma biomarker and detection system and kit thereof | |
| EP4314830A1 (en) | Use of microvesicles for benign colorectal polyps and colorectal cancer screening | |
| CN116027048A (en) | Cytokine storm syndrome diagnosis kit and application thereof | |
| CN117347633A (en) | CD45 + CD8 + HLA-DRB5 + Application of T cells in preparation of kit for assisting in diagnosis of aplastic anemia and graft-versus-host disease | |
| Nasiri et al. | Accuracy of Paris 2016 System for Non-invasive Diagnosis Bladder Malignancy | |
| Pertiwi | Maritsatun Nisa, Andina Putri Aulia, Rahayu. Hematological and Biochemical Parameters at Admission as Predictors for Mortality in Patients with Moderate to Severe COVID-19 | |
| CN116500262A (en) | Immunosenescence biomarker, detection system and kit thereof | |
| CN114141364A (en) | anti-PD-1 single-drug treatment effectiveness evaluation system based on peripheral blood immune cell map |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |